PR Newswire Asia's news > Biotechnology

< Previous page

All Airlines/Aviation Auto Maritime/Shipbuilding Transportation Computer Hardware Computer Networks Computer Software Computer/Electronics Electronic Commerce Electronic Components High Tech Security Internet Technology Peripherals Semiconductors Electronics Gaming Consumer Electronics Mobile Entertainment Multimedia/Online/Internet Telecommunications Household/Consumer/Cosmetics Retail Supermarkets Toys Alternative Energies Chemical Mining/Metals Oil/Energy Environmental Products & Services Green Technology Art Cosmetics & Personal Care Entertainment Fashion Film & Motion Picture Jewelry Banking/Financial Service Insurance Workforce Management/Human Resources Education Higher Education Biotechnology Health Care/Hospital Infectious Disease Control Medical Equipment Medical/Pharmaceuticals Agriculture Machinery Paper/Forest Products/Containers Textiles Domestic policy Legal issues Sports Hotels and Resorts Leisure/Travel/Hotels Travel Restaurants Beer, Wine & Spirits Beverages Non-Alcoholic Beverages Food/Beverages Advertising Books Music Publishing/Information Service Television Trade show news Real Estate Construction/Building Furniture & Furnishings  |   Title only   |   Print

Next page >

88IV - PR Newswire Asia's news - Biotechnology 5 REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora ... 2026-09-01T    Biotechnology   Cosmetics & Personal Care   Medical/Pharmaceuticals  Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development NANJING, China , Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket ... 2026-09-01T    Biotechnology   Computer Hardware   Computer/Electronics   Health Care/Hospital  Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel ROCKVILLE, Md. , Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  JIANGXI BIO Announced 2026 Interim Results Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody ... 2026-09-01T    Banking/Financial Service   Biotechnology   Chemical   Health Care/Hospital  Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis "From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75% [1] , [2] " ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Company to host a corporate update call Tuesday, September 1st at 8:00am ET ... 2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals  Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases SUZHOU, China , Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today ... 2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals
< Previous page	Next page >